MedImmune gets nod for new vaccine tech

MedImmune announced that the FDA has approved its use of reverse genetics to make new vaccines. The new procedure significantly narrows the number of gene segments researchers study when creating a new vaccine, allowing a manufacturer like MedImmune to better target its research efforts and speed development. MedImmune has already used reverse genetics to develop an experimental vaccine for the H5N1 virus. It currently is in Phase I.

- check out the report on MedImmune from the Washington Business Journal